Patents Assigned to Sterrenbeld Biotechnologie North America, Inc.
-
Publication number: 20180296641Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: ApplicationFiled: April 5, 2018Publication date: October 18, 2018Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo L. Arguelles, Gustavo Vera Janavel, Jose Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
-
Publication number: 20170252405Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: ApplicationFiled: April 18, 2017Publication date: September 7, 2017Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo L. Arguelles, Gustavo Vera Janavel, Jose Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacia Pichel, Marcelos Eduardo Criscuolo
-
Publication number: 20160346352Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.Type: ApplicationFiled: June 6, 2016Publication date: December 1, 2016Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo L. Arguelles, Gustavo Vera Janavel, Jose Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacia Pichel, Marcelos Eduardo Criscuolo
-
Publication number: 20140341972Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.Type: ApplicationFiled: February 10, 2014Publication date: November 20, 2014Applicants: Fundacion Universitaria Dr. Rene G. Favaloro, Sterrenbeld Biotechnologie North America, Inc.Inventors: RUBÉN LAGUENS, MARCELO L. ARGUELLES, GUSTAVO VERA JANAVEL, JOSÉ ALBERTO CROTTOGINI, CARLOS ALBERTO MELO, RICARDO HORACIA PICHEL, MARCELOS EDUARDO CRISCUOLO
-
Publication number: 20110072526Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct comprising the hGH gene and beta casein promoter sequences conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: ApplicationFiled: May 17, 2010Publication date: March 24, 2011Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Alberto Melo, Lino Baranao, Cesar Horacio Carbonetto
-
Patent number: 7807862Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: GrantFiled: September 29, 2004Date of Patent: October 5, 2010Assignee: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Alberto Melo, Lino Baranao
-
Patent number: 7718845Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: GrantFiled: September 29, 2004Date of Patent: May 18, 2010Assignee: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Alberto Melo, Lino Baranao, Cesar Horacio Carbonetto
-
Patent number: 7638296Abstract: The present invention relates, in general, to a method for the massive culture of recombinant mammalian cells for the production of recombinant human erythropoietin (EPO) in culture medium containing insulin. The present invention also refers to a method of producing EPO and to the EPO thus produced.Type: GrantFiled: November 8, 1999Date of Patent: December 29, 2009Assignee: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Miguel Carcagno, Marcelo Eduardo Criscuolo, Carlos Alberto Melo, Miguel Alejandro Vidal
-
Publication number: 20090275645Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: ApplicationFiled: June 18, 2009Publication date: November 5, 2009Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Rubén Laguens, Marcelo L. Arguelles, Gustavo Leónidas Vera Janavel, José Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
-
Publication number: 20090228999Abstract: The invention relates to a non-human transgenic mammal that is useful for the production of a protein of interest that may be toxic to the mammal. The mammal is characterized by the fact that it is transgenic for the production in its milk of an inactive form of the protein of interest, preferably recombinant human insulin. It is not possible to produce recombinant human insulin in transgenic mammals since this molecule has a certain degree of biological activity in the mammals and could be toxic to the mammal. Thus, the invention involves cloning a genetic construct comprising a sequence encoding a modified human insulin precursor under the control of a beta casein promoter in an expression vector. It also involves transfecting the expression plasmid into fetal bovine somatic cells, such as fibroblasts, and enucleating bovine oocytes by nuclear transfer to generate transgenic embryos.Type: ApplicationFiled: June 13, 2008Publication date: September 10, 2009Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: A. BERCOVICH, A. PRYNC, N. Fernandez, C. Melo, M. Criscuolo
-
Publication number: 20090187999Abstract: The invention relates to a non-human transgenic mammal that is useful for the production of a protein of interest that may be toxic to the mammal. The mammal is characterized by the fact that it is transgenic for the production in its milk of an inactive form of the protein of interest, preferably recombinant human insulin. It is not possible to produce recombinant human insulin in transgenic mammals since this molecule has a certain degree of biological activity in the mammals and could be toxic to the mammal. Thus, the invention involves cloning a genetic construct comprising a sequence encoding a modified human insulin precursor under the control of a beta casein promoter in an expression vector. It also involves transfecting the expression plasmid into fetal bovine somatic cells, such as fibroblasts, and enucleating bovine oocytes by nuclear transfer to generate transgenic embryos.Type: ApplicationFiled: June 13, 2008Publication date: July 23, 2009Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: A. BERCOVICH, A. Prync, C. Melo, N. Fernandez, N. Judewicz, M. Criscuolo
-
Patent number: 7563777Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: GrantFiled: November 17, 2003Date of Patent: July 21, 2009Assignees: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Rubén Laguens, Marcelo L. Argüelles, Gustavo Leónidas Vera Janavel, José Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
-
Publication number: 20080229438Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: ApplicationFiled: July 11, 2007Publication date: September 18, 2008Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Alberto Melo, Lino Baranao
-
Publication number: 20080060089Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: ApplicationFiled: July 11, 2007Publication date: March 6, 2008Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Melo, Lino Baranao, Cesar Carbonetto
-
Patent number: 7012130Abstract: The present invention relates, in general, to a method of purifying recombinant human erythropoietin (EPO). The present invention also relates to a substantially pure EPO. The method comprises a differential precipitation, an hydrophobic interaction chromatography, various concentration and diafiltration steps, tandem anionic and cationic exchange chromatographies and molecular exclusion chromatography for the obtaining of pure EPO. The method does not comprise high performance liquid chromatography steps. The invention also comprises the EPO obtained according to the claimed procedure.Type: GrantFiled: November 8, 1999Date of Patent: March 14, 2006Assignee: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Miguel Carcagno, Marcelo Eduardo Criscuolo, Carlos Alberto Melo, Juan A. Vidal
-
Publication number: 20050177878Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: ApplicationFiled: September 29, 2004Publication date: August 11, 2005Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Melo, Lino Baranao
-
Publication number: 20050177879Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.Type: ApplicationFiled: September 29, 2004Publication date: August 11, 2005Applicant: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Melo, Lino Baranao, Cesar Carbonetto
-
Publication number: 20050020522Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.Type: ApplicationFiled: November 17, 2003Publication date: January 27, 2005Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo Arguelles, Gustavo Leonidas Janavel, Jose Crottogini, Carlos Melo, Ricardo Pichel, Marcelo Criscuolo
-
Patent number: 6777205Abstract: The gene coding for human erythropoietin (EPO) was obtained from human genomic DNA. Thc gene used does not include sequences from regions at i 5′ of the first translated ATG and ii 3′ of the stop codon of the EPO gene. The gene was cloned into an expression plasmid for eukaryotic cells that have as sole expression control elements the early promoter of the SV40 virus and its polyadenylation signal. Recombinant cells resulting from transfection with genetic constructs used provide an unexpectedly high level of protein expression of 50 mg of recombinant EPO per liter of culture medium per day.Type: GrantFiled: November 6, 2001Date of Patent: August 17, 2004Assignee: Sterrenbeld Biotechnologie North America, Inc.Inventors: Carlos Miguel Carcagno, Marcelo Eduardo Criscuolo, Carlos Alberto Melo, Juan Alejandro Vidal